Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gisa Ellrichmann

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Experimental Neurology|January 9, 2018
Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's diseaseOluwaseun Fatoba, Eugen Kloster, Christiane Reick, et al.
Experimental Neurology|September 3, 2016
Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's diseaseChristiane Reick, Gisa Ellrichmann, Teresa Tsai, et al.
Plos One|February 8, 2011
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's diseaseGisa Ellrichmann, Elisabeth Petrasch-Parwez, De-Hyung Lee, et al.
Journal of Neurology|November 1, 2018
Peripheral CD19<sup>+</sup> B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disordersGisa Ellrichmann, Jan Bolz, Maren Peschke, et al.
Journal of Neuroinflammation|May 8, 2020
Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cellsThomas Grüter, Alina Blusch, Jeremias Motte, et al.
Therapeutic Advances in Neurological Disorders|August 11, 2021
Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosisMaike F Dohrn, Gisa Ellrichmann, Rastislav Pjontek, et al.
Brain and Behavior|November 6, 2025
Epidemiology of Parkinson's Disease in Germany Between 2016 and 2021 Based on Statutory Health Insurance Claims DataDirk Woitalla, Gisa Ellrichmann, Stefan Jun Groiss, et al.
Scientific Reports|July 12, 2017
Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
Scientific Reports|March 16, 2019
Author Correction: Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
Plos One|May 23, 2013
Diagnostic value of the impairment of olfaction in Parkinson's diseaseSwaantje Casjens, Angelika Eckert, Dirk Woitalla, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Experimental Neurology|January 9, 2018
Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's diseaseOluwaseun Fatoba, Eugen Kloster, Christiane Reick, et al.
Experimental Neurology|September 3, 2016
Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's diseaseChristiane Reick, Gisa Ellrichmann, Teresa Tsai, et al.
Plos One|February 8, 2011
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's diseaseGisa Ellrichmann, Elisabeth Petrasch-Parwez, De-Hyung Lee, et al.
Journal of Neurology|November 1, 2018
Peripheral CD19<sup>+</sup> B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disordersGisa Ellrichmann, Jan Bolz, Maren Peschke, et al.
Journal of Neuroinflammation|May 8, 2020
Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cellsThomas Grüter, Alina Blusch, Jeremias Motte, et al.
Therapeutic Advances in Neurological Disorders|August 11, 2021
Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosisMaike F Dohrn, Gisa Ellrichmann, Rastislav Pjontek, et al.
Brain and Behavior|November 6, 2025
Epidemiology of Parkinson's Disease in Germany Between 2016 and 2021 Based on Statutory Health Insurance Claims DataDirk Woitalla, Gisa Ellrichmann, Stefan Jun Groiss, et al.
Scientific Reports|July 12, 2017
Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
Scientific Reports|March 16, 2019
Author Correction: Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
Plos One|May 23, 2013
Diagnostic value of the impairment of olfaction in Parkinson's diseaseSwaantje Casjens, Angelika Eckert, Dirk Woitalla, et al.
Pageof 6